Session » Osteoporosis and Metabolic Bone Disease – Clinical Aspects and Pathogenesis

Date: Sunday, November 13, 2016

Time: 4:30PM-6:00PM

Meeting: 2016 ACR/ARHP Annual Meeting

Abstract Number: 1023

Fracture Risk Reduction with Romosozumab: Results of a Phase 3 Study in Postmenopausal Women with Osteoporosis

Abstract Number: 1024

Superior Gains in Bone Mineral Density and Estimated Strength at the Hip for Romosozumab Compared with Teriparatide in Women with Postmenopausal Osteoporosis Transitioning from Bisphosphonate Therapy: Results of a Phase 3, Open-Label Clinical Trial

Abstract Number: 1025

Assessment of the Effects of Switching Bisphosphonates to Denosumab or Daily Teriparatide in Patients with Rheumatoid Arthritis

Abstract Number: 1026

Morphea-like Skin Lesions Reported in the Phase 3 Long-Term Odanacatib Fracture Trial and Extension in Postmenopausal Women with Osteoporosis

Abstract Number: 1027

Odanacatib Efficacy and Safety in Postmenopausal Women with Osteoporosis: 5-Year Data from the Extension of the Phase 3 Long-Term Odanacatib Fracture Trial

Abstract Number: 1028

Discontinuation of Denosumab and Associated Vertebral Fracture Incidence: Analysis from a Phase 3 Placebo-Controlled Study of Denosumab and Its Open-Label Extension

« View all sessions from this meeting